Results 151 to 160 of about 28,682 (177)

Human medicines European public assessment report (EPAR): IntronA, interferon alfa-2b, Carcinoid Tumor,Leukemia, Hairy Cell,Lymphoma, Follicular,Hepatitis B, Chronic,Hepatitis C, Chronic,Leukemia, Myelogenous, Chronic, BCR-ABL Positive,Melanoma,Multiple Myeloma, Date of authorisation: 09/03/2000, Re

Case Medical Research, 2019

semanticscholar   +2 more sources

[Two Ph chromosome positive chronic myelogenous leukemia patients with rare bcr/abl fusion gene].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2008
To investigate the unusual bcr/abl fusion gene structures of two Ph chromosome positive chronic myelogenous leukemia (CML) patients in chronic phase (CP).By using general M- and micro -bcr/abl specific primers respectively, bcr/abl fusion transcripts were detected by reverse transcription-polymerase chain reaction (RT-PCR).
Ya-zhen, Qin, Yan-rong, Liu, Jin-lan, Li, Hui, Wang, Yan, Chang, Jia-yu, Fu, Guo-rui, Ruan, Hui-lin, Shi, Jing-ying, Qiu, Dao-pei, Lu, Shan-shan, Chen   +10 more
openaire   +2 more sources

Flow cytometric assay of phosphotyrosine levels in Bcr-Abl-positive chronic myelogenous leukemias: a potential prognostic marker

Annals of Hematology, 2008
Assay of phosphotyrosine levels using flow cytometry has been used to identify patients with chronic myelogenous leukemia positive for the Bcr-Abl fusion gene. We hypothesized that clinical monitoring could identify treatment response through reductions in intragranulocyte phosphotyrosine.
Xuemei, Sun, Jianyong, Li, Junhao, Chen, Dong, Li, Leilei, Chen, Wei, Xu, Yonggong, Yang, Yujie, Wu, Pengjun, Jiang, Wei, Xie   +9 more
openaire   +2 more sources

Concomitant JAK2 V617F-Positive Polycythemia Vera and BCR-ABL-Positive Chronic Myelogenous Leukemia Treated with Ruxolitinib and Dasatinib.

Blood, 2012
Abstract Abstract 2832 Co-occurrence of a JAK2 V617F-positive myeloproliferative neoplasm (MPN) with BCR-ABL-positive chronic myelogenous leukemia (CML) in a single patient is rare. Previous reports have suggested that the two disorders may arise independently or within the same clone, but definitive clonal analysis has ...
Eric M. Knoche, Daniel A.C. Fisher, Gregory Rippberger, Li He, Deborah M. Moore, Jonathan L. Klein, Stephen T. Oh   +6 more
openaire   +1 more source

Relationship of the type of bcr-abl hybrid mRNA to clinical course and transforming activity in philadelphia-positive chronic myelogenous leukemia

Leukemia Research, 1992
We studied the type of bcr-abl mRNA for 34 patients with chronic myelogenous leukemia and analyzed for correlations among the mRNA type, the clinical outcome and the transforming activity using the tumorigenicity assay. There was no difference in the distribution of the mRNA-types (b2-a2 and b3-a2) between clinical phases.
M, Futaki, K, Inokuchi, H, Matsuoka, K, Miyake, K, Dan, T, Nomura   +5 more
openaire   +2 more sources

Philadelphia-positive chronic myelogenous leukemia with typical bcr/abl molecular features and atypical, prolonged survival.

Leukemia, 1989
Despite the major breakthrough in the knowledge of the molecular events underlying the t(9;22) translocation, still no consistent data have been found on the evolution of Ph1 positive CML from the chronic to the accelerated or blastic phase of the disease.
Selleri L., Emilia G., Temperani P., Grassilli E., Zucchini P., Tagliafico E., Bonati A., Venezia L., Ferrari S., Torelli U., Torelli G.   +10 more
openaire   +2 more sources

Absence of the hybrid bcr‐abl mRNA in Ph¹‐positive B lymphoblastoid cell lines established from a patient with chronic myelogenous leukemia

International Journal of Cancer, 1987
AbstractThe expression of c‐abl, c‐sis, c‐myc and N‐ras oncogenes was examined in 2 lymphoblastoid cell lines, one with Ph1 (PB‐1049) and the other without Ph1 (LN‐1049), both established from a patient with chronic myelogenous leukemia (CML), and in a Ph1‐positive cell line (PB‐1049‐T) derived from a tumor formed after transplantation of PB‐1049 cells
T, Yamada, T, Oikawa, N, Kuzumaki, N, Takagi, M, Sasaki   +4 more
openaire   +2 more sources

Preliminary activity of AMN107, a novel potent oral selective Bcr-Abl tyrosine kinase inhibitor, in newly diagnosed Philadelphia chromosome (Ph)-positive chronic phase chronic myelogenous leukemia (CML-CP)

Journal of Clinical Oncology, 2006
6591 Background: AMN107 is a novel, highly selective oral Bcr-Abl inhibitor which is 20–50-fold more potent than imatinib. High response rates with AMN107 were observed in all CML phases post imatinib failure. Methods: Study Aims: Evaluate the efficacy of AMN107in newly diagnosed Ph-positive CML-CP.
E. Jabbour, F. Giles, J. Cortes, S. O’Brien, F. Ravandi, G. Borthakur, G. Garcia-Manero, L. Letvak, A. Salvado, H. Kantarjian   +9 more
openaire   +2 more sources

New Genetic Variation in BCR gene of Major B3a2 Breakpoint BCR-ABL Fusion Gene in Patients with Chronic Myelogenous Leukemia in Yogyakarta, Indonesia

Asian Pacific Journal of Cancer Prevention, 2017
Background: Polymorphic bases in several exons of the BCR gene have been found in several studies of the BCR-ABL fusion gene. Most of the polymorphisms do not have any implications for the primary structure of the BCR-ABL protein.
Tri Agusti Sholikah, S. H. Hutajulu, Dewi Sulistyawati, Sumartiningsih Aning, S. Fatmawati, Anditta Syifarahmah, K. Widayati, J. Kurnianda, D. K. Paramita   +8 more
semanticscholar   +1 more source

Imatinib resistant chronic myelogenous leukemia, BCR-ABL positive by chromosome and FISH analyses but negative by PCR, in a child progressing to acute basophilic leukemia: cytogenetic follow-up

Cancer Genetics and Cytogenetics, 2006
The case of an 11-year-old child with adult-type chronic myeloid leukemia, Philadelphia (BCR-ABL) positive, reverse transcription-polymerase chain reaction negative for the major, minor, and micro breakpoints is presented. In the course of 3 years, the child failed to respond to treatment with hydroxyurea, refused all therapy for 6 months, was ...
Asher M, Moser, Esther, Manor, Ginat, Narkis, Joseph, Kapelushnik   +3 more
openaire   +2 more sources